Opinion

Video

TKI Monotherapy Data in Non–Clear Cell RCC

Author(s):

Benjamin Garmezy, MDMartin H. Voss, MD

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
5 KOLs are featured in this program
5 KOLs are featured in this program
Brian I. Rini, MD, FASCO
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
Related Content
Brian Rini, MD, of Vanderbilt Cancer Center
July 21st 2024

KIM-1 Demonstrates Potential Utility as a Biomarker With Worse DFS Outcomes in KIM-1–High RCC

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Toni Choueiri, MD
July 18th 2024

Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
June 6th 2024

Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations

Andrea B. Apolo, MD, of the National Institutes of Health
July 15th 2024

Cabozantinib Plus Nivolumab Shows Efficacy With/Without Ipilimumab Across Advanced GU Malignancies

Sidi Chen, PhD
July 14th 2024

Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer Therapy